Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dimethyl fumarate attenuates cerebral edema formation by protecting the blood-brain barrier integrity.
Multiple Sclerosis and Catastrophic Health Expenditure in Iran.
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
Generation of demyelination models by targeted ablation of oligodendrocytes in the zebrafish CNS.
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
The cell biology of CNS myelination.
Is No Evidence of Disease Activity a Realistic Goal for Patients With Multiple Sclerosis?
FDA product review for daclizumab
Immunology of Multiple Sclerosis.
How integrated are neurology and palliative care services? Results of a multicentre mapping exercise.
Results from Two Phase III Studies Added to U.S. Label of Genzyme’s Aubagio
[Prevalence of multiple sclerosis in the Region of Murcia].
Identification of naturally occurring Fatty acids of the myelin sheath that resolve neuroinflammation.
Voiding Dysfunction in Multiple Sclerosis.
Low-contrast acuity measures visual improvement in phase 3 trial of natalizumab in relapsing MS.
Myeloid cell transmigration across the CNS vasculature triggers IL-1β-driven neuroinflammation during autoimmune encephalomyelitis in mice.
Movement and structure of mitochondria in oligodendrocytes and their myelin sheaths.
Multiple sclerosis review.
Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.
CinnoVex home page
Clinical Epigenetics International Meeting
Switch to natalizumab vs fingolimod in active relapsing-remitting multiple sclerosis.
Treatment with Trichuris suis soluble products during monocyte-to-macrophage differentiation reduces inflammatory responses through epigenetic remodeling.
Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis.

Pages